Valneva reports positive 12-month antibody persistence data for single-shot chikungunya vaccine candidate

Saint - herblain ( france), december 5 , 2022 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today reported positive antibody persistence data twelve months after vaccination with a single dose of its chikungunya vaccine candidate, vla1553.
VALN Ratings Summary
VALN Quant Ranking